C57BL/6-Alms1-del

Gout/Hyperuricemia Models and Efficacy Services
Monosodium Urate (MSU)-induced Gouty Arthritis ModelsUrate Oxidase Knockout (Uox-KO) Gout Models
Hyperlipidemia Models and Efficacy Services
hPCSK9-UTR ModelshPCSK9 Models
Atherosclerosis Models and Efficacy Services
Ldlr KO ModelsApoE KO Models
Liver Disease Models and Efficacy Services
CCl4-induced Liver Fibrosis ModelsHFD+CCl4-induced MASH ModelsBKS-db MASH ModelsB6-Alms1-del MASH ModelsOther MASH Models
Type II Diabetes Models and Efficacy Service
HFHSD+STZ Induced Diabetes ModelsBKS-db
Obesity Models and Efficacy Services
Wild Mouse 750C57BL/6-Alms1-del45% HFHSD Induced Obesity(DIO) models60% HFD Induced Obesity (DIO) models

Data Validation

1. Body weight

图片1.png

Figure 1. Body weight curves of C57BL/6-Alms1-del mice vs control mice. Data are presented as Mean±SEM.


2. Glucose tolerance test

图片2.png

Figure 2. After ten weeks, studies on glucose tolerance were carried out on C57BL/6-Alms1-del mice. We measured blood glucose levels at 0, 15, 30, 60, 90, and 120 minutes. C57BL/6-Alms1-del mice have lower glucose tolerance, when compared to the control group. Data are presented as Mean±SD, with n=5. ****, p<0.0001; by unpaired two-tailed Student's t-test.


3. Serum insulin levels

图片4.png

Figure 3. Insulin levels were significantly increased in C57BL/6-Alms1-del mices. Data are presented as Mean±SD, n=5. ****, p<0.0001; by unpaired two-tailed Student's t-test.


4. Blood lipid levels

图片5.png

图片6.png

Figure 4. The hyperlipidemic phenotype of C57BL/6-Alms1-del mice became more severe with age. Data are presented as Mean±SD, n=5. **，p<0.05，**，p<0.01；***, p<0.001；****, p<0.0001; by unpaired two-tailed Student's t-test.


5. Liver enzymes

图片7.png图片7.png

Figure 5. After 16 weeks, C57BL/6-Alms1-del mice showed liver damage.Data are presented as Mean±SD, n=5. **，p<0.01；****, p<0.0001; by unpaired two-tailed Student's t-test.


6. Fatty liver phenotype

图片8.png

Figure 6. After 21 weeks, C57BL/6-Alms1-del mice developed a severe fatty liver phenotype that included steatosis, inflammation, and cellular vacuolation lesions.


7. Expression of inflammation, fibrosis-related biomarkers

图片9.png

Figure 7. Expression levels of inflammatory, fibrosis-related markers were significantly increased in C57BL/6-Alms1-del mice. Data are presented as Mean±SD, n=5. **，p<0.05，**，p<0.01；***, p<0.001; by unpaired two-tailed Student's t-test.


Efficacy data

1. Semaglutide reduced the body weight, food intake and fasting blood glucose

图片1.png

图片1.png

Figure 8. Semaglutide significantly reduced body weight, food intake, and postpranpranal blood glucose levels in B6-AIms1-del mice. Data are presented as Mean±SD. *，p<0.05；**，p<0.01；***，p<0.001; by unpaired two-tailed Student's t-test.


2. Liver enzymes and blood lipid levels

图片3.png

图片4.png

Figure 9. Semaglutide significantly improved liver function and dyslipidemia of the B6-Alms1-del model. Data are presented as Mean±SD.***, p<0.001;****, p<0.0001 by unpaired two-tailed Student's t-test.


3. Semaglutide improved liver function 

图片5.png图片5.png

Figure 10. Semaglutide significantly improved hepatic steatosis, inflammation, and ballooning in the B6-Alms1-del model. Data are presented as Mean±SD.*, p<0.05 by unpaired two-tailed Student's t-test.


TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。